BIO Notebook Day 1: Other Therapeutic Areas Left Behind As Deal-Making, Financing Focus On Oncology, Rare Diseases

BIO is investigating why psychiatric, cardiovascular and some other disease areas draw less deal-making and investment interest. Trillium CEO Niclas Stiernholm talks about the relative lack of VC funding for Canadian biotechs. And Novartis' Jay Bradner shares progress from the company's entrepreneurial NIBR Scholars experiment.